ACEON? 8 mg: CV event reduction (CV mortality or nonfatal MI) in stable CAD patients, even in patients ≤ 55 years of age
* EUROPA: 20% relative risk reduction of the combined primary endpoint in 12,218 stable CAD patients
o CV mortality, nonfatal MI, or cardiac arrest [perindopril 488 (8.0%) vs placebo 603 (9.9%)] (P=0.0003) 1,2
o Approximately one-third of patients in the study were aged 55 years or less 1,2
* The benefit was consistent across all predefined subgroups regardless of gender, age, or underlying disease 1,2
* ACEON? provides benefits in patients receiving contemporary CV protective therapies 1,2
*
ACEON? provides continuous 24-hour BP control that is clinically proven with convenient dosing 3,4
Indicated in Patients With Stable Coronary Artery Disease 2
ACEON? is indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. ACEON? can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive, or lipid-lowering therapy.
ACEON? is also indicated for the treatment of patients with essential hypertension.
USE IN PREGNANCY 2
When used in pregnancy, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ACEON? should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
